Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Assets (2016 - 2026)

Organogenesis Holdings has reported Assets over the past 11 years, most recently at $598.7 million for Q4 2025.

  • For Q4 2025, Assets rose 20.25% year-over-year to $598.7 million; the TTM value through Dec 2025 reached $598.7 million, up 20.25%, while the annual FY2025 figure was $598.7 million, 20.25% up from the prior year.
  • Assets for Q4 2025 was $598.7 million at Organogenesis Holdings, up from $509.8 million in the prior quarter.
  • Over five years, Assets peaked at $598.7 million in Q4 2025 and troughed at $319.2 million in Q1 2021.
  • A 5-year average of $449.5 million and a median of $453.3 million in 2022 define the central range for Assets.
  • Biggest five-year swings in Assets: skyrocketed 64.24% in 2021 and later decreased 3.53% in 2024.
  • Year by year, Assets stood at $443.3 million in 2021, then grew by 1.38% to $449.4 million in 2022, then grew by 2.37% to $460.0 million in 2023, then rose by 8.23% to $497.9 million in 2024, then grew by 20.25% to $598.7 million in 2025.
  • Business Quant data shows Assets for ORGO at $598.7 million in Q4 2025, $509.8 million in Q3 2025, and $461.1 million in Q2 2025.